Asian Pacific Journal of Cancer Prevention

  • 제15권9호
  • /
  • Pages.3911-3914
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Application of Tumor Markers SCC-Ag, CEA, and TPA in Patients with Cervical Precancerous Lesions

  • Farzaneh, Farah (Preventive Gynecology Research Center, Department of Obstetrics and Gynecology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Shahghassempour, Shapour (Tissue Engineering and Nanomedicine Research Center, Taleghani Teaching Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Noshine, Bahram (Tissue Engineering and Nanomedicine Research Center, Taleghani Teaching Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Arab, Maliheh (Preventive Gynecology Research Center, Department of Obstetrics and Gynecology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Yaseri, Mehdi (Clinical Research and Development Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Rafizadeh, Mitra (Department of Pathology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences) ;
  • Alizadeh, Kamyab (Preventive Gynecology Research Center, Department of Obstetrics and Gynecology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences)
  • 발행 : 2014.05.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: To determine the potential clinical utility of tumor markers CEA, TPA, and SCC-Ag for early detection of cervical precancerous lesions. Materials and Methods: A case-control study was carried out on 120 women (46 patients with histologically confirmed cervical precancerous lesions and 74 healthy controls). The significance of serum selected tumor markers in early detection of cervical intraepithelial neoplasia (CIN) were assessed. Results: Of the case group, the rates of CIN I, II, III, was 69.6%, 23.9%, and 6.5%, respectively. According to the manufacturer's cut-off values of 2ng/ml, 5ng/ml, and 70 U/ml for SCC-Ag, CEA and TPA tests, in that order, SCC-Ag test had a sensitivity of 13%, but CEA and TPA tests could not distinguish between case and control groups. The diagnostic sensitivities were highest at cut-off values of 0.55 ng/ml for SCC-Ag, 2.6ng/ml for CEA, and 25.5 U/ml for TPA which were 93%, 61%, and 50%, respectively. However, the area under the receiver operating characteristic curve was the largest for SCC-Ag (0.95 vs. 0.61 and 0.60 for CEA and TPA, respectively). Moreover, there was a highly significant direct correlation between SCC-Ag concentration and the degree of cervical precancerous lesions (r=0.847, p<0.001). Conclusions: The new cutoff of 0.5 for SCC-Ag test might be useful as a tumor marker in Iranian patients with CIN and it needs to be more evaluated by studies with larger populationa.

키워드

참고문헌

  1. Chen C, Yang Z, Li Z Li L (2012). Accuracy of several cervical screening strategies for early detection of cervical cancer: a meta-analysis. Int J Gynecol Cancer, 22, 908-21. https://doi.org/10.1097/IGC.0b013e318256e5e4
  2. Cuzick J, Arbyn M, Sankaranarayanan R, et al (2008). Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine, 10, 29-41.
  3. Esajas MD, Duk JM, de Bruijn HW, et al (2001). Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol, 19, 3960-6. https://doi.org/10.1200/JCO.2001.19.19.3960
  4. Forni F, Ferrandina G, Deodato F, et al (2007). Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys, 69, 1145-9. https://doi.org/10.1016/j.ijrobp.2007.04.055
  5. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR (2004). Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother, 58, 24-38. https://doi.org/10.1016/j.biopha.2003.11.003
  6. Hong JH, Tsai CS, Chang JT, et al (1998). The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys, 41, 823-30. https://doi.org/10.1016/S0360-3016(98)00147-3
  7. Indarti J, Aziz MF, Suryawati B, Fernando D (2013). Scoring system and management algorithm assessing the role of survivin expression in predicting progressivity of HPV infections in precancerous cervical lesions. Asian Pac J Cancer Prev, 14, 1643-7. https://doi.org/10.7314/APJCP.2013.14.3.1643
  8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  9. Jeong BK, Choi DH, Huh SJ, et al (2011). The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiat Oncol J, 29, 191-8. https://doi.org/10.3857/roj.2011.29.3.191
  10. Jesdapatarakul S, Tangjitgamol S, Nguansangiam S, Manusirivithaya S (2011). Liqui-Prep(R) versus conventional Papanicolaou smear to detect cervical cells abnormality by split-sample technique: a randomized double-blind controlled trial. Diagn Cytopathol, 39, 22-7. https://doi.org/10.1002/dc.21320
  11. Juang CM, Wang PH, Yen MS, et al (2000). Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol, 76, 103-6. https://doi.org/10.1006/gyno.1999.5665
  12. Kato H, Torigoe T (1977). Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer, 40, 1621-8. https://doi.org/10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I
  13. Mathew A, George PS (2009). Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide. Asian Pac J Cancer Prev, 10, 645-50.
  14. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
  15. Parkin DM, Almonte M, Bruni L, et al (2008). Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine, 11, 1-15.
  16. Porika M, Vemunoori AK, Tippani R, et al (2010). Squamous cell carcinoma antigen and cancer antigen 125 in Southern Indian cervical cancer patients. Asian Pac J Cancer Prev, 11, 1745-7.
  17. Reesink-Peters N, van der Velden J, Ten Hoor KA, et al (2005). Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol, 23, 1455-62. https://doi.org/10.1200/JCO.2005.02.123
  18. Takeshima N, Hirai Y, Katase K, et al (1998). The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol, 68, 263-6. https://doi.org/10.1006/gyno.1998.4939
  19. Tendler A, Kaufman HL, Kadish AS (2000). Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum Pathol, 31, 1357-62. https://doi.org/10.1016/S0046-8177(00)80004-0
  20. Volgger B, Aspisirengil C, Genser-Krimbacher E, et al (2008). Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. Cancer Lett, 262, 183-9. https://doi.org/10.1016/j.canlet.2007.12.005
  21. Wallace D, Hunter J, Papenfuss M, et al (2007). Pap smear screening among women >/=40 years residing at the United States-Mexico border. Health Care Women Int, 28, 799-816. https://doi.org/10.1080/07399330701563111

피인용 문헌

  1. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease vol.37, pp.1, 2016, https://doi.org/10.1007/s13277-015-3914-0
  2. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing vol.13, pp.1, 2018, https://doi.org/10.1186/s13027-018-0178-5